Published in Pharmaceuticals (Basel) on June 01, 2010
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
Selected major risk factors and global and regional burden of disease. Lancet (2002) 24.47
Replicating genotype-phenotype associations. Nature (2007) 16.11
Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet (2010) 14.81
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA (2003) 14.77
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Human hypertension caused by mutations in WNK kinases. Science (2001) 8.71
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ (2004) 7.92
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am J Hum Genet (2010) 5.39
Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell (1994) 5.29
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet (1995) 4.45
Essential hypertension. Part I: definition and etiology. Circulation (2000) 3.59
Genome-wide mapping of human loci for essential hypertension. Lancet (2003) 3.53
Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med (2004) 2.79
The genetic dissection of essential hypertension. Nat Rev Genet (2006) 2.77
Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science (2000) 2.21
Better blood pressure control: how to combine drugs. J Hum Hypertens (2003) 2.19
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 1.96
Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension (1987) 1.80
Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community. Hypertension (2000) 1.70
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int (2002) 1.64
Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet (1992) 1.55
Emergence of sex differences in prevalence of high systolic blood pressure: analysis of a longitudinal adolescent cohort. Circulation (2006) 1.52
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens (2008) 1.41
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther (2008) 1.37
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther (2006) 1.31
Positional identification of hypertension susceptibility genes on chromosome 2. Hypertension (2004) 1.25
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 1.23
Age at puberty and adult blood pressure and body size in a British birth cohort study. J Hypertens (2006) 1.20
Sources of measurement variation in blood pressure in large-scale epidemiological surveys with follow-up. Blood Press (2002) 1.20
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension (2005) 1.18
Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension (2008) 1.17
Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens (1991) 1.17
Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens (2009) 1.16
Twins in cardiovascular genetic research. Hypertension (2001) 1.15
Selective genetic advantages for users of thiazide diuretics. Is there a case for the 460Trp variant of alpha-adducin? J Hypertens (2009) 1.11
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J (2008) 1.05
Hypertension and genome-wide association studies: combining high fidelity phenotyping and hypercontrols. J Hypertens (2008) 1.03
Systematic, genome-wide, sex-specific linkage of cardiovascular traits in French Canadians. Hypertension (2008) 0.97
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J (2006) 0.95
Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med (1984) 0.94
beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens (2008) 0.91
The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade. J Hum Hypertens (2008) 0.91
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am J Cardiol (2007) 0.89
Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens (1998) 0.88
The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. J Hypertens (2010) 0.87
Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension Study. Hypertension (2006) 0.86
An investigation of genome-wide associations of hypertension with microsatellite markers in the family blood pressure program (FBPP). Hum Genet (2007) 0.84
Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr Opin Cardiol (2009) 0.83
Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA (1992) 0.82
The influence of genetics and household environment upon the variability of normal blood pressure: the Montreal Adoption Survey. Clin Exp Hypertens A (1986) 0.81
Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol Sci (2005) 0.80
Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int (1993) 0.80
Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int Suppl (1988) 0.76